Last reviewed · How we verify
Ergobasine (Ergometrine)
At a glance
| Generic name | Ergometrine |
|---|---|
| Also known as | Mitrotan, Active Comparator |
| Sponsor | Cairo University |
| Drug class | ergometrine |
| Target | 5-hydroxytryptamine receptor 1D |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- Postabortal Hemorrhage
- Postpartum hemorrhage
Common side effects
Key clinical trials
- Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy (NA)
- Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial (PHASE4)
- Prophylactic Methylergonovine for Twin Cesarean (PHASE4)
- Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium (NA)
- Misoprostol Versus Active Management of Labour in CS (PHASE1)
- Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients (PHASE4)
- Protocols for Prevention of PPH During CS in High Risk Group
- Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ergobasine CI brief — competitive landscape report
- Ergobasine updates RSS · CI watch RSS
- Cairo University portfolio CI